Is concomitant aspirin helping novel oral anticoagulants? Focus on apixaban

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10293479" target="_blank" >RIV/00064203:_____/14:10293479 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/14:10293479

Result on the web

<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189222/" target="_blank" >http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189222/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1136/openhrt-2014-000134" target="_blank" >10.1136/openhrt-2014-000134</a>

Result language

angličtina

Original language name

Is concomitant aspirin helping novel oral anticoagulants? Focus on apixaban

Original language description

Apixaban is the third novel oral anticoagulant approved by the Food and Drug Administration for the reduction in the risk of stroke in patients with atrial fibrillation. Apixaban showed a significant reduction in mortality as well as a reduction in strokes compared with warfarin in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.1 However, it is unclear how much of this 'benefit' was derived from the negative benefit to risk ratio (RR) when combining aspirin with warfarin compared with warfarin alone. Approximately one-third of patients received combination warfarin-acetylsalicylic acid (ASA) therapy in ARISTOTLE at baseline (31.3% on apixaban, 30.5% on warfarin), with approximately 20-25% of patients receiving aspirin with long-term anticoagulation,2 despite the fact that only 14% of patients randomised to warfarin had a definitive indication for concomitant aspirin therapy (ie, patients having a previous myocardial infarct

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FB - Endocrinology, diabetology, metabolism, nutrition

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Open Heart

ISSN

2053-3624

e-ISSN

—

Volume of the periodical

1

Issue of the periodical within the volume

1

Country of publishing house

GB - UNITED KINGDOM

Number of pages

2

Pages from-to

—

UT code for WoS article

—

EID of the result in the Scopus database

—